中国生物制药(01177)拟收购主要股东旗下公司股权以收购正大天晴5%股权 涉资44.8亿元

金吾财讯
Sep 11

金吾财讯 | 中国生物制药(01177)发布公告,公司拟通过向主要股东收购Sino Harmony Ventures Limited雍华创投有限公司的股权,以收购正大天晴5%股权,代价为44.8亿元人民币。

正大天晴为公司的附属公司,于交割时,公司间接持有正大天晴的股权将由60%增加至65%。以2026年6月底正大天晴LTM经调整归母净利润计,可增厚集团经调整归母净利润约7.4%(即约3.5亿人民币)。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10